Akèy › Fibroz sistik › Kansas › Kansas City
Etid klinik pou Fibroz sistik nan Kansas City, KS
13 etid pou Fibroz sistik ap chèche patisipan nan sit nan ak bò kote Kansas City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Phase 2 Study to Assess the Safety and Efficacy of ANG003
Ap rekriteFaz 2
- University of Kansas Medical Center, Kansas City
Sinus Disease in Young Children With Cystic Fibrosis
Ap rekriteEtid obsèvasyon
- University of Kansas Medical Center, Kansas City
Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children
Ap rekriteEtid obsèvasyon
- University of Kansas Medical Center, Kansas City
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
Ap rekriteFaz 4
- University of Kansas Medical Center, Kansas City
4D-710 in Adult Patients With Cystic Fibrosis
Ap rekriteFaz 2
- University of Kansas Medical Center, Kansas City
Evaluation of Ventilation Defects Downstream of Mucus Plugs in Patients With Muco-Obstructive Lung Disease
Ap rekriteEtid obsèvasyon
- University of Kansas Medical Center, Kansas City
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
Ap rekriteFaz 1Volontè an sante akeyi
- University of Kansas Medical Center, Kansas City
Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function
Ap rekriteFaz 2
- University of Kansas Medical Center, Kansas City
Health Outcomes of Parents With Cystic Fibrosis-Aim 2
Ap rekriteEtid obsèvasyon
- University of Kansas Medical Center, Kansas City
Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)
Ap rekriteEtid obsèvasyon
- Kansas University Medical Center, Kansas City
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
Ap rekriteEtid obsèvasyon
- University of Kansas Medical Center, Kansas City
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
Ap rekriteFaz 2
- University of Kansas Medical Center, Kansas City
A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)
Ap rekriteFaz 1/2
- University of Kansas Medical Center, Kansas City
Etid Fibroz sistik nan lòt vil
- Boston, MA17 etid
- Birmingham, AL16 etid
- Philadelphia, PA15 etid
- Seattle, WA12 etid
- Baltimore, MD12 etid
- Denver, CO11 etid
- Dallas, TX11 etid
- Pittsburgh, PA11 etid
- Cincinnati, OH10 etid
- Los Angeles, CA9 etid
- Aurora, CO9 etid
- Charleston, SC8 etid
Lòt etid nan Kansas City
- Maladi kadyovaskilè14 etid
- Ensifizyans kadyak13 etid
- Obèsite13 etid
- Maladi poumon entèstisyèl13 etid
- Kansè nan tete12 etid
- Kansè vejik12 etid
- Leksemi mieloïd egi12 etid
- Kansè pwostat12 etid
- Kansè Poumon ki pa ti selil11 etid
- Kansè poumon11 etid
- BPCO9 etid
- Asm8 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.